International Lung Cancer Summit

Registration is now open for the 7th International Lung Cancer Summit #ILCS25! Connect with our hosts, @Alfdoc2 & @peters_solange, and leading experts to get the latest developments in thoracic oncology 🫁 🗓️ 26 September from 9:30AM CEST ⬇️ Secure your seat early

Register now for #DCLung25 - a can't miss, one-day, @IASLC endorsed lung cancer conference on Saturday, October 4th in Washington DC. Hear from experts like Dr. Hoss Borghaei @HosseinBorghaei, who will discuss immunotherapy advances for NSCLC. medstarhealth.org/dclung25

Available @JTOonline - the 2024 @IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness. jto.org/article/S1556-…

More options for patients mean more complexity for clinicians. @DrJNaidoo, @GautschiOliver, and @nicogirardcurie unpack how to navigate new treatment options in NSCLC for key subgroups like brain mets using emerging data to guide decisions. Watch the full session online ⬇️

Two powerful perspectives. One critical decision. In this high-stakes debate @tnewsomdavis defends osimertinib, while @LeXiuning makes the case for amivantamab + lazertinib. What’s the smarter frontline strategy in EGFR+ metastatic NSCLC? Join the ILCS on 26ᵗʰ September & decide

Fantastic work together with @Alfdoc2 @jillfeldman4 and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. @MDAndersonNews @lungoncdoc @OncoViews @oncodaily

@stephanieplsaw from Singapore will present the latest advances in targeting HER2 and MET in NSCLC – highlighting how new strategies are tackling resistance mutations and expanding the reach of precision oncology. Come to the ILCS and gain fresh clinical insights ⬇️

Update to the @ASCO Living Guidelines for NSCLC with driver alterations now @JCO_ASCO from @Joshua_Reuss et al to include zenocutuzumab for patients with NSCLC that harbors an #NRG1 fusion. ascopubs.org/doi/10.1200/JC…

Friends and community at the #ALKSummit2025 - Stronger Together with @DrMarkAwad @christine_lovly @NarjustFlorezMD @JessicaJLinMD @exercise_cancer and Angel Qin @ALKPositiveinc

🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…

What’s next in the evolving landscape of EGFR and ALK targeting in NSCLC? 🫁 @TommyJohn00 from Australia will explore where we are – and what’s ahead for personalized strategies that drive outcomes. ✅ Register now for the ILCS on 26ᵗʰ September and join the conversation ⬇️

In this episode of the @IASLC podcast, Lung Cancer Considered, I discuss recently approved sunvozertinib for #EGFR NSCLC with an exon 20 insertion with Dr. James Yang and Dr. @MariamAlex26. Download wherever you get your podcasts or link below! iaslc.org/iaslc-news/lun…

Behind every biomarker is a person. It was an honor to co-author this comprehensive review on optimizing treatment for #EGFRm #NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… It isn't easy for a patient/advocate to contribute meaningfully to long, technical articles, but that's exactly why…

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team…

In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…

Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer - 18m-PFS 65.5% N, 66.3% I/N - mOS 32m, NR - g3+ TRAE 18.5% v 29.4% Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI jitc.bmj.com/content/13/7/e…

FLAURA2 or MARIPOSA? Which strategy delivers lasting benefit in EGFR-mutated NSCLC? We will debate this question during our annual ILCS. Until then, hear thoughts from @DrJNaidoo, @nicogirardcurie & @GautschiOliver how OS data may impact our decisions. Watch the full session now

Could pathological complete response become the key to curing lung cancer – and even challenge the traditional role of surgery in patients with multistation N2 disease? Watch the full roundtable with @peters_solange, @FordePatrick & @JordiRemon to get the answers on our website.

Meet our first speaker at the ILCS: @md_mariusilie from France. Join us on 26ᵗʰ September with our chairs @Alfdoc2 & @peters_solange as he explores how cutting-edge diagnostic techniques and emerging tools are transforming lung cancer care. ⬇️ Register Now

@triparnasen gives a masterclass presentation on SCLC subtypes, their biological significance & implication for possible treatments @etop_ibcsg

Looking at the latest data from ASCO for SCLC, why does the OS benefit seem stronger than PFS? Is there a real plateau in the data? And how should we interpret non-significant subgroups? Watch the answers from @peters_solange, @g_mountzios & @sands_jacob and the full recording 📊